We think its portfolio and pipeline support a wide moat, and with the HCV market stabilizing, Gilead needs strong continued innovation in HIV, solid oncology pipeline data, and smart future ...

Animal health company Zoetis (NYSE:ZTS) will be reporting results tomorrow before market open. Here’s what to look for.

Chinese consumers, once the engine of growth for multinational companies, are cutting back on all kinds of things. Designer handbags, luxury face creams and trips to Paris have all fallen victim to ...

Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives ...

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron ...

A new twist on value has investors waking up to the beauty of companies returning gobs of cash to shareholders.

Data on enfortumab vedotin plus pembrolizumab for advanced bladder cancer, along with updates on antibody-drug conjugates, biomarkers, and other cancer treatments, will be highlighted at the American ...

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...